EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results

Hyunkyung Yun, Jin Kim, Aishwarya Gandhe, Brianna Nelson, Jim C Hu, Vikas Gulani, Daniel Margolis, Bruce R Schackman, Ali Jalali

JAMA Network Open · 29.11.2023 · 6 (11) · e2344856

DOI: 10.1001/jamanetworkopen.2023.44856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 29.11.2023. Verfasst von Hyunkyung Yun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Magnetic resonance imaging (MRI) and potential MRI-guided biopsy enable enhanced identification of clinically significant prostate cancer. Despite proven efficacy, MRI and potential MRI-guided biopsy remain costly, and there is limited evidence regarding the cost-effectiveness of this approach in general and for different prostate-specific antigen (PSA) strata.

Objective

To examine the cost-effectiveness of integrating annual MRI and potential MRI-guided biopsy as part of clinical decision-making for men after being screened for prostate cancer compared with standard biopsy. Design, Setting, and Participants Using a decision analytic Markov cohort model, an economic evaluation was conducted projecting outcomes over 10 years for a hypothetical cohort of 65-year-old men in the US with 4 different PSA strata (<2.5 ng/mL, 2.5-4.0 ng/mL, 4.1-10.0 ng/mL, >10 ng/mL) identified by screening through Monte Carlo microsimulation with 10 000 trials. Model inputs for probabilities, costs in 2020 US dollars, and quality-adjusted life-years (QALYs) were from the literature and expert consultation. The model was specifically designed to reflect the US health care system, adopting a federal payer perspective (ie, Medicare). Exposures Magnetic resonance imaging with potential MRI-guided biopsy and standard biopsy. Main Outcomes and Measures Incremental cost-effectiveness ratios (ICERs) using a willingness-to-pay threshold of $100 000 per QALY was estimated. One-way and probabilistic sensitivity analyses were performed.

Results

For the 3 PSA strata of 2.5 ng/mL or greater, the MRI and potential MRI-guided biopsy strategy was cost-effective compared with standard biopsy (PSA 2.5-4.0 ng/mL: base-case ICER, $21 131/QALY; PSA 4.1-10.0 ng/mL: base-case ICER, $12 336/QALY; PSA >10.0 ng/mL: base-case ICER, $6000/QALY). Results varied depending on the diagnostic accuracy of MRI and potential MRI-guided biopsy. Results of probabilistic sensitivity analyses showed that the MRI and potential MRI-guided biopsy strategy was cost-effective at the willingness-to-pay threshold of $100 000 per QALY in a range between 76% and 81% of simulations for each of the 3 PSA strata of 2.5 ng/mL or more. Conclusions and Relevance This economic evaluation of a hypothetical cohort suggests that an annual MRI and potential MRI-guided biopsy was a cost-effective option from a US federal payer perspective compared with standard biopsy for newly eligible male Medicare beneficiaries with a serum PSA level of 2.5 ng/mL or more.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsUnited StatesAgedMaleHumansProstate-Specific AntigenCost-Benefit AnalysisMedicareImage-Guided BiopsyMagnetic Resonance Imaging

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York.
  • Department of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, Rhode Island.
  • Department of Urology, Weill Cornell Medicine, Cornell University, New York, New York.
  • Department of Radiology, University of Michigan Health System, Ann Arbor.
  • Department of Radiology, Weill Cornell Medicine, Cornell University, New York, New York.

Zitieren

APA

Yun, H., Kim, J., Gandhe, A., Nelson, B., Hu, J. C., Gulani, V., Margolis, D., Schackman, B. R., & Jalali, A. (2023). Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results. JAMA Network Open, 6(11), e2344856. https://doi.org/10.1001/jamanetworkopen.2023.44856

Vancouver

Yun H, Kim J, Gandhe A, Nelson B, Hu JC, Gulani V, et al. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results. JAMA Network Open. 2023;6(11):e2344856. doi:10.1001/jamanetworkopen.2023.44856

BibTeX
@article{Yun2023,
  author = {Yun, Hyunkyung and Kim, Jin and Gandhe, Aishwarya and Nelson, Brianna and Hu, Jim C and Gulani, Vikas and Margolis, Daniel and Schackman, Bruce R and Jalali, Ali},
  title = {Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {11},
  pages = {e2344856},
  doi = {10.1001/jamanetworkopen.2023.44856}
}
Kostenlos starten →